The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation

Ren, Jianghao; Liu, Ruijun

doi:10.1007/978-1-0716-3346-5_10

Cited by 1 publication

(1 citation statement)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, despite all the promising preliminary results described above, there are no clinical trials yet demonstrating that liquid biopsy-based treatment actually improves outcomes in pancreatic cancer patients. However, encouragingly, recent trials in colon and lung cancer have proven that liquid biopsies possess the potential to meaningfully impact patient survival [28,29]. In the near future, currently ongoing prospective and interventional clinical trials will determine whether treatment decisions based on liquid biopsies can enhance care for patients with PDAC.…”

Section: Liquid Biopsies To Guide Treatment and Monitor Recurrencementioning

confidence: 99%

Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence

Daamen,

Molenaar,

Groot

2023

JCM

View full text Add to dashboard Cite

The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising. While surgical techniques and peri-operative care have improved, the overall survival for PDAC remains poor. Thus, novel and bold research initiatives are needed along the spectrum of clinical care, a few of which will be discussed in this article. Early detection is crucial, with specific high-risk groups possibly benefiting from targeted screening programs. Liquid biopsies (such as circulating exosomes, tumor DNA, or tumor cells) offer promise as multifunctional biomarkers for early detection, treatment guidance, and recurrence monitoring. Precision medicine is being explored via targeted therapies for actionable mutations, such as PARP inhibitors for BRCA mutations, and immunotherapy strategies. Artificial intelligence (AI) is emerging as a powerful tool in medical imaging, biomarker discovery, genetics research, and treatment planning, and it can aid in diagnosis, treatment selection, and patient monitoring. However, its associated challenges include ethics, data security, algorithm reliability, and validation. Collaborative efforts between medical professionals, researchers, and AI experts are vital for unlocking AI’s potential to enhance pancreatic cancer care. In conclusion, despite the challenges, advancements in liquid biopsies, precision medicine, and AI offer hope for enhancing the diagnosis, treatment, and management of pancreatic cancer.

show abstract

Section: Liquid Biopsies To Guide Treatment and Monitor Recurrencementioning

confidence: 99%

Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence

Daamen,

Molenaar,

Groot

2023

JCM

View full text Add to dashboard Cite

show abstract

The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation

Cited by 1 publication

References 129 publications

Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence

Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence

Contact Info

Product

Resources

About